<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080920</url>
  </required_header>
  <id_info>
    <org_study_id>Rosmalip®-OnCOVInf</org_study_id>
    <nct_id>NCT05080920</nct_id>
  </id_info>
  <brief_title>Rosmalip® for Cancer Infections Prevention</brief_title>
  <acronym>OnCOVInf</acronym>
  <official_title>A Pilot, Randomized, Double Blind, Placebo Controlled Study to Evaluate an Immune System Modulator Nutritional Supplement for the Prevention of Infections in Cancer Patients Receiving Oncologic Treatment During the COVID-19 Pandemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IMDEA Food</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and efficacy of Rosmalip® nutritional supplement&#xD;
      compared to placebo in subjects with solid cancer for the prevention of infections including&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer patients undergoing oncologic treatments frequently have comorbidities and suffer&#xD;
      immunosuppresion, toxicities and exposure to nosocomial pathogens. As a result, they are at&#xD;
      increased risk of infections, including COVID-19. It is of utmost importance to find&#xD;
      therapies that can prevent infections with as less toxicity as possible. Rosmalip® is a&#xD;
      nutritional supplement developed as a molecular nutrition, composed of a rosemary&#xD;
      supercritical extract at concentrations approved by EFSA -with in vitro and in vivo antitumor&#xD;
      effects that are independent of its antioxidant and anti-inflammatory properties- in a&#xD;
      lipidic vehicle that has shown in preclinical and clinical studies to potentiate innate&#xD;
      immunity without apparent toxicity. Being a product of easy synthesis its effects on&#xD;
      immunity, inflammation and cancer, could be of interest to prevent and ameliorate infections,&#xD;
      including COVID-19.&#xD;
&#xD;
      In this pilot study it is hypothesized that Rosmalip® could help to prevent or ameliorate&#xD;
      infections, including COVID-19, in oncologic patients under active treatment. Secondarily, it&#xD;
      is also hypothesized to have metabolic beneficial effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants receive Rosmalip® capsule or Placebo tablet matching Rosmalip® orally once daily for 16 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of infectious events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of infectious events according to International Sepsis Forum Consensus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of SARSCoV2 infections</measure>
    <time_frame>6 months</time_frame>
    <description>Number of PCR confirmed SARSCoV2 infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of metabolic and immune profile</measure>
    <time_frame>6 months</time_frame>
    <description>Evolution of levels of expression of a panel of genes related to lipid metabolism, inflammation and immune system in peripheral blood mononuclear cells and d-dimer,C-reactive protein, and NLR (neutrophils to lymphocytes ratio)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infections</condition>
  <condition>Covid19</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Rosmalip®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Rosmalip® (diterpene phenols 11,25 mg) 1 capsule orally once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive Placebo 1 capsule matching Rosmalip® orally once daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rosmalip®</intervention_name>
    <description>Nutritional Supplement+Usual Care</description>
    <arm_group_label>Rosmalip®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo+Usual Care</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a solid cancer under active Anticancer Treatment (including&#xD;
             Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy)&#xD;
&#xD;
          -  Informed consent signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies to fish&#xD;
&#xD;
          -  Vitamin, Antioxidants consumers and who would no accept to stop taking them 1 week&#xD;
             before and during the study&#xD;
&#xD;
          -  Disphagia&#xD;
&#xD;
          -  Bilirrubin higher than 1.5 Upper Normal Limit (UNL)/ Creatinin &gt; 1.5 UNL&#xD;
&#xD;
          -  Severe organic dysfunction&#xD;
&#xD;
          -  Cardiac dysfunction&#xD;
&#xD;
          -  Cholangitis/ Biliary tract obstruction&#xD;
&#xD;
          -  Immunodeficiency or Immflamatory disease (HIV, Inflammatory Bowel Disease,&#xD;
             Collagenosis)&#xD;
&#xD;
          -  Dementia or Psychiatric severe disease&#xD;
&#xD;
          -  Pregnancy or Breastfeeding&#xD;
&#xD;
          -  Previous diseases that interfere lipid carrier absorption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Casado Sáenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Oncología. Hospital Infanta Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Ramírez de Molina, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IMDEA Food</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Reglero Rada, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CIAL_UAM_CSIC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servicio de Oncología. Hospital Infanta Sofía.</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28134</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.alibird.org/2020-CM/</url>
    <description>ALIBIRD_Therapeutic strategies for precision nutrition in cancer patients</description>
  </link>
  <reference>
    <citation>Mouhid L, Corzo-Martínez M, Torres C, Vázquez L, Reglero G, Fornari T, Ramírez de Molina A. Improving In Vivo Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems. J Oncol. 2017;2017:7351976. doi: 10.1155/2017/7351976. Epub 2017 May 7. Review.</citation>
    <PMID>28555156</PMID>
  </reference>
  <results_reference>
    <citation>Gómez de Cedrón M, Laparra JM, Loria-Kohen V, Molina S, Moreno-Rubio J, Montoya JJ, Torres C, Casado E, Reglero G, Ramírez de Molina A. Tolerability and Safety of a Nutritional Supplement with Potential as Adjuvant in Colorectal Cancer Therapy: A Randomized Trial in Healthy Volunteers. Nutrients. 2019 Aug 24;11(9). pii: E2001. doi: 10.3390/nu11092001.</citation>
    <PMID>31450563</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Vallinas M, Reglero G, Ramírez de Molina A. Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy. Nutr Cancer. 2015;67(8):1221-9. doi: 10.1080/01635581.2015.1082110. Epub 2015 Oct 9. Review.</citation>
    <PMID>26452641</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Vallinas M, Molina S, Vicente G, Sánchez-Martínez R, Vargas T, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A. Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells. Electrophoresis. 2014 Jun;35(11):1719-27. doi: 10.1002/elps.201400011. Epub 2014 Mar 20.</citation>
    <PMID>24615943</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Vallinas M, Molina S, Vicente G, Zarza V, Martín-Hernández R, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A. Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer. PLoS One. 2014 Jun 3;9(6):e98556. doi: 10.1371/journal.pone.0098556. eCollection 2014.</citation>
    <PMID>24892299</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Vallinas M, Molina S, Vicente G, de la Cueva A, Vargas T, Santoyo S, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A. Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res. 2013 Jun;72:61-8. doi: 10.1016/j.phrs.2013.03.010. Epub 2013 Apr 1.</citation>
    <PMID>23557932</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares</investigator_affiliation>
    <investigator_full_name>Enrique Casado Sáenz</investigator_full_name>
    <investigator_title>Head of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

